Sinking fatty rafts

Jado Technologies GmbH believes its ability to selectively target lipid rafts could succeed in treating conditions such as inflammation and infectious disease where these structures are uniquely associated with specific events implicated in disease.

On Monday this week, the company was to announce the start of a Phase IIa trial of a reprofiled compound to treat cutaneous mastocytosis that Jado believes works by disrupting lipid rafts on mast

Read the full 673 word article

How to gain access

Continue reading with a
two-week free trial.